We focus on non-small cell lung cancers (NSCLCs) for which approximately 20% of patients show a K-RAS activating mutation (e.g., K-RAS G12D or K-RAS G12C) (Figure 1B). Here, KRAS is linked to non-small cell lung carcinoma.